Dr. Harrison on Choosing Frontline Treatment for RCC

Michael R. Harrison, MD
Published: Thursday, Nov 30, 2017



Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Considering the data with cabozantinib (Cabometyx) versus ipilimumab (Yervoy) and nivolumab (Opdivo), the field is changing so rapidly. There is going to be data of those combinations with checkpoint inhibitors and anti-VEGF agents, but the future lies in other combinations, explains Harrison.

According to Harrison, axitinib (Inlyta) would also be reasonable since it has a second-line approval and is being investigated in clinical trials.
 


Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Considering the data with cabozantinib (Cabometyx) versus ipilimumab (Yervoy) and nivolumab (Opdivo), the field is changing so rapidly. There is going to be data of those combinations with checkpoint inhibitors and anti-VEGF agents, but the future lies in other combinations, explains Harrison.

According to Harrison, axitinib (Inlyta) would also be reasonable since it has a second-line approval and is being investigated in clinical trials.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x